Share

    


In This Section

Home / Learn / Precision Medicine

Precision Medicine

Precision medicine (also known as personalized medicine) uses information about a person’s genes, proteins, and environment to prevent, diagnose, and treat cancer. Precision medicine includes the use of biomarkers, molecular testing, and targeted therapies to deliver a personalized approach to cancer therapy through the use of molecular and genomic information about individual cancers. The National Cancer Institute (NCI) defines precision medicine as “discovering unique therapies that treat an individual’s cancer based on the specific abnormalities of their tumor.”

From Oncology Issues

  •  Building a Personalized Medicine Program
    Thomas D. Brown, MD, MBA
    The Swedish Cancer Institute (SCI) has a long history of providing the nurturing care of a community-based hospital while giving patients access to the latest cancer therapies. In 2013 we took on the question of how to integrate personalized, genomic medicine into our program.
  •  How Molecular Subtyping is Changing Our Understanding of Breast Cancer
    James V. Pellicane, MD, FACS
    This article describes molecular subtyping and shows how it is changing both the understanding of breast cancer and how to treat it. The article summarizes the most important new studies and details the impact of this new information for community cancer centers.
  •  Molecular Testing in the Community Setting
    In 2013, ACCC proceeded with Phase II, Learning Labs for Process Improvement, a program for member institutions that focused on improving molecular testing at the system level through experiential learning labs.
  •  How Lean Methodology can Improve Molecular Testing Processes in Advanced NSCLC
    Lawrence D. Wagman, MD, FACS; Raymond Casciari, MD; John Maurice, MD; Peggy J. Crabtree, MBA, RN; and Ruslan Horblyuk, PhD, MBA
    To see how lean methodology could be used to evaluate current molecular testing processes, identify waste, and design an improved process for advanced non-small cell lung cancer (NSCLC) in the community setting, a pilot study was conducted at St. Joseph Hospital, Orange, Center for Cancer Prevention and Treatment (SJH), located in Orange County, Calif.
  •  Using a Collective Brain to Defeat the Deadliest Brain Tumor
    David F. Arons, JD
    Sometimes referred to as the “terminator,” glioblastoma (GBM) is one of the deadliest forms of brain cancer.
  •  Best of ASCO 2017
    Cary A. Presant, MD, FACP, FASCO
    ASCO 2017 was filled with new information and long lines as 39,000 oncologists worldwide came together to hear the latest advances in cancer care.
  •  A Model for Tissue Banking in the Community Setting
    Viorela Pop; Lavinia Dobrea; Sandra Brown; Noah Gonzalez; Rachelle Alquitela; Ron Bati; Martha French; Sonia Labeet; Melinda Lima; Virginia Trujillo Castro; Nancy Walter; Sarah M. Barrett; Aaron Sassoon; and Lawrence D. Wagman
    Banking of biological specimens can advance oncology research efforts by providing valuable resources from participants and promoting collaborative partnerships.
  •  The Study of High-Cost Oncology Patients to Improve Care & Curb Costs
    Matthew A. Manning, MD
    This article shares how Cone Health System identified high-cost patients, or “hot-spotters,” and put processes and systems in place to not only improve care for these patients but also reduce costs.
  •  Prostate Cancer Detection & Diagnosis: Opening Up New Therapeutic Avenues
    James S. Wysock, MD, and Herbert Lepor, MD
    ND16-Prostate-Cancer-Detection-&-Diagnosis-Opening-up-new-therapeutic-avenues
  •  Best of ASCO 2016
    Cary A. Presant, MD, FACP, FASCO
    The 2016 ASCO Annual Meeting was filled with information, practice advice, and exciting results that will change oncology for the coming year.

Additional Resources

NCCN Policy Report: Developments in Molecular Testing and Biosimilars (requires login)
Winckworth-Prejsnar K, Nardi EA, Lentz L, et al. NCCN Policy Report: Developments in Molecular Testing and Biosimilars. J Natl Compr Cancer Netw. 2017;15(6):772-782. 

Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine
Craig LA, Phillips JK, Moses HL. (eds.) Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine. Washington, DC: National Academies Press; 2016.

ACCC and CAP TODAY webinar: CAP/AMP/IASLC Guidelines for NSCLC: Current Experience and Future Update Four national thought-leaders examine current guidelines, planned updates, and provide expert feedback on the impact of these guidelines on practices.
This webinar was originally broadcast on Nov. 30, 2016.